Successful preconceptional prophylactic treatment with combined acetyl salicylic acid and low-molecular heparin (Fragmin®) in a case of antiphospholipid-antibody syndrome with prior life-threatening hemolysis, elevated liver enzymes and low-platelet syndr

2005 ◽  
Vol 84 (12) ◽  
pp. 1213-1214 ◽  
Author(s):  
Kjell Haram ◽  
Line Björge ◽  
Per Morten Sandset
Keyword(s):  
Salicylic Acid ◽  
Prophylactic Treatment ◽  
Liver Enzymes ◽  
Acetyl Salicylic Acid ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Elevated Liver Enzymes ◽  
Life Threatening

Regression of early events of atherosclerosis in hypercholesterolemic rabbits by prophylactic treatment with nitroderivative of acetyl salicylic acid

2001 ◽  
Vol 53 (4) ◽  
pp. 237-243
Author(s):  
Mohamed Z. Gad ◽  
Mahmoud M. Khattab ◽  
Nadia A. Moustafa ◽  
Jean-Luc Burgaud
Keyword(s):  
Salicylic Acid ◽  
Prophylactic Treatment ◽  
Acetyl Salicylic Acid

scholarly journals The rheumatology/hematology interface: CAPS and MAS diagnosis and management

Hematology ◽  
2018 ◽  
Vol 2018 (1) ◽  
pp. 313-317 ◽  
Author(s):  
John M. Gansner ◽  
Nancy Berliner
Keyword(s):  
Lupus Erythematosus ◽  
Macrophage Activation ◽  
Early Recognition ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Rheumatologic Disease ◽  
Rheumatologic Diseases ◽  
Life Threatening ◽  
Vessel Thrombosis ◽  
Timely Treatment

Abstract Catastrophic antiphospholipid antibody syndrome (CAPS) and macrophage activation syndrome (MAS) are both life-threatening hematologic disorders that infrequently afflict patients with rheumatologic disease. CAPS is characterized by fulminant multiorgan damage related to small vessel thrombosis in the setting of persistent antiphospholipid antibodies. It can occur in patients with rheumatologic diseases such as systemic lupus erythematosus but can also affect patients who do not have rheumatologic disease. By contrast, the term MAS is applied when patients with rheumatologic disease develop hemophagocytic lymphohistiocytosis (HLH); therefore, patients with MAS have an underlying rheumatologic disease by definition. Similar to CAPS, HLH/MAS can have a fulminant presentation, but the pathogenesis and manifestations are different. In both CAPS and MAS, management generally includes but is not limited to immunosuppression with steroids. Fatalities are relatively common and morbidity is often significant. Early recognition of these disorders and initiation of timely treatment are important. More effective therapies for both syndromes are urgently needed.

scholarly journals Women's Experiences of Preeclampsia: Australian Action on Preeclampsia Survey of Women and Their Confidants

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
C. East ◽  
K. Conway ◽  
W. Pollock ◽  
N. Frawley ◽  
S. Brennecke
Keyword(s):  
Liver Enzymes ◽  
Response Rate ◽  
Normal Pregnancy ◽  
Substantial Effect ◽  
Postal Survey ◽  
Access To Information ◽  
Consumer Group ◽  
Elevated Liver Enzymes ◽  
Life Threatening ◽  
Close Relatives

Introduction. The experience of normal pregnancy is often disrupted for women with preeclampsia (PE).Materials and Methods. Postal survey of the 112 members of the consumer group, Australian Action on Pre-Eclampsia (AAPEC).Results. Surveys were returned by 68 women (61%response rate) and from 64 (57%) partners, close relatives or friends. Respondents reported experiencing pre-eclampsia (n=53), eclampsia (n=5), and/or Hemolysis, Elevated Liver enzymes, and Low Platelets (HELLP syndrome) (n=26). Many women had no knowledge of PE prior to diagnosis (77%) and, once diagnosed, did not appreciate how serious or life threatening it was (50%). Women wanted access to information about PE. Their experience contributed substantial anxiety towards future pregnancies. Partners/friends/relatives expressed fear for the woman and/or her baby and had no prior understanding of PE.Conclusions. The PE experience had a substantial effect on women, their confidants, and their babies and affected their approach to future pregnancies. Access to information about PE was viewed as very important.

HEPARIN IN HUMAN PLACENTAL DEVELOPMENT AND THE PREVENTION OF PLACENTAL COMPLICATIONS OF PREGNANCY

2010 ◽  
Vol 21 (3) ◽  
pp. 185-203 ◽  
Author(s):  
SASCHA DREWLO ◽  
MELISSA WALKER ◽  
ANNE MCLEOD ◽  
JODIE DODD ◽  
JOHN KINGDOM
Keyword(s):  
Pregnant Women ◽  
Heart Valves ◽  
Oral Drug ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Placental Development ◽  
Treatment And Prevention ◽  
Large Numbers ◽  
Life Threatening ◽  
Thrombotic Complications

The development of effective anticoagulant drugs available for use in pregnancy has resulted in dramatic improvements for a number of potentially life-threatening conditions. These include the treatment and prevention of venous thromboembolism and the thrombotic complications of antiphospholipid antibody syndrome, as well as the management of pregnant women with mechanical heart valves. The most commonly used class of drug includes heparin, a highly-charged macro-molecule that does not cross the placenta, in contrast to the potentially teratogenic and fetotoxic oral drug warfarin. This review will focus on our current lack of understanding of the wider actions of heparin and examines the possibility that large numbers of pregnant women are presently being treated inappropriately with heparin.

Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome

Lupus ◽  
2010 ◽  
Vol 19 (9) ◽  
pp. 1071-1077 ◽  
Author(s):  
C. Frances
Keyword(s):  
Clinical Significance ◽  
Antiphospholipid Syndrome ◽  
Scientific Data ◽  
Livedo Reticularis ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Antithrombotic Agents ◽  
Cutaneous Necrosis ◽  
Life Threatening ◽  
Optimum Management

The dermatological manifestations of antiphospholipid syndrome (APS) may be the presenting features of APS syndrome. They are extremely diverse and heterogeneous, ranging from minor signs to life-threatening conditions such as widespread cutaneous necrosis. Their clinical significance is highly variable. Livedo reticularis is strongly associated with the arterial and microangiopathic subtypes of APS. Scientific data are required to determine the optimum management of these patients, who might benefit from recently developed antithrombotic agents. Lupus (2010) 19, 1071—1077.

scholarly journals Normotensive HELLP syndrome in the midst of Dengue fever

2018 ◽  
Vol 9 (2) ◽  
pp. 40-42
Author(s):  
Robin George Manappallil ◽  
Sithara Surendran ◽  
Anoop Kumar ◽  
Ganga Prasad
Keyword(s):  
Blood Pressure ◽  
Risk Factor ◽  
Dengue Fever ◽  
Hellp Syndrome ◽  
Liver Enzymes ◽  
Elevated Blood ◽  
Medical Sciences ◽  
Elevated Liver Enzymes ◽  
Life Threatening ◽  
Life Threatening Complication

HELLP syndrome is a life threatening complication of pregnancy, characterized by haemolysis, elevated liver enzymes and low platelet counts. Preeclampsia is a risk factor for developing HELLP. However, some patients can have HELLP in the absence of elevated blood pressure. Dengue fever is a mosquito-borne viral infection characterized by fever, leucopenia and thrombocytopenia, and bleeding manifestations. This is a case of a young primigravida who presented with dengue fever and was found to have an associated normotensive HELLP syndrome.Asian Journal of Medical Sciences Vol.9(2) 2018 40-42

Sign in / Sign up

Export Citation Format

Share Document